J&J-Partnered Addex Fails Phase II Epilepsy Study, Mulls Future of Candidate

Johnson & Johnson-partnered Addex Therapeutics on Monday announced that ADX71149, the companies’ investigational modulator of the metabolic glutamate subtype 2 receptor, did not meet its primary efficacy endpoint in a Phase II epilepsy study.